Time flies when you are having fun and feels like April was over before we could even get ourselves completely settled in and back on track.
As the markets struggled for direction so too did our dividend portfolio. At times it seemed like April was going to be a banner month as earnings overall were turning out somewhat better than expected. Then our account took a hit with the earnings release for Abbvie (ABBV) which is the largest position in our portfolio. The subsequent drop in the stock price was a bit odd as the numbers were actually pretty good, but the erosion in the sales of their flagship drug after losing patent protection was just too much and the stock sold off.
Over the last couple of trading days the markets rallied and ABBV recovered a small portion of the drop. Our portfolios roller coaster ride ended slightly in the positive for the month which we are always happy to see. Of concern going forward is the continued volatility, continued fed incompetence and yet another bank failure which could have further negative impact on the economy and the markets.
Continue reading “April 2023 Dividend Portfolio Update”